SCHEMBL4075643

SCHEMBL4075643

Cc1cccc(-c2cnc(N)nc2NCCCN2CCCC2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 2/20 0.52
IRAK4 Q9NWZ3 5/20 0.48
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
ADORA1 P30542 1/20 0.47
FGFR1 P11362 2/20 0.45
KDR P35968 2/20 0.45
TLR8 Q9NR97 3/20 0.44
TLR7 Q9NYK1 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
PIK3CG P48736 1/20 0.42
BRD4 O60885 1/20 0.42
TAF1 P21675 1/20 0.42
ATAD2 Q6PL18 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4108173 0.99 ACP1 (0.53) ACP1IRAK4KDM4EMEN1ALDH1A1
SCHEMBL4100539 0.98 IRAK4 (0.51) ACP1IRAK4KDM4EMEN1ALDH1A1
SCHEMBL4112794 0.97 ACP1 (0.52) ACP1IRAK4KDM4EMEN1ALDH1A1
SCHEMBL4110711 0.91 TLR8 (0.46) ACP1IRAK4KDM4EMEN1ALDH1A1
SCHEMBL4078984 0.90 ADORA1 (0.47) ACP1IRAK4KDM4EMEN1ALDH1A1
SCHEMBL4107200 0.89 IRAK4 (0.49) ACP1IRAK4KDM4EMEN1ALDH1A1
SCHEMBL4121742 0.89 IRAK4 (0.62) IRAK4KDM4EMEN1ALDH1A1POLB
SCHEMBL4078662 0.88 CYP1A2 (0.54) ACP1IRAK4KDM4EALDH1A1KMT2A
SCHEMBL4112210 0.88 IRAK4 (0.47) ACP1IRAK4KDM4EMEN1ALDH1A1
SCHEMBL4078120 0.88 ACP1 (0.52) ACP1IRAK4ADORA1FGFR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054392-A2 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES AS INHIBITORS OF PROTEIN KINASE C-ALPHA Boehringer Ingelheim International GmbH (DE) 2009-05-06 EP claimed
WO-2007146981-A2 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES AS INHIBITORS OF PROTEIN KINASE C-ALPHA BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-21 WO claimed
US-20070293494-A1 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines DJUNG JANE F 2007-12-20 US claimed
US-8354407-B2 2-anilino-4-(heterocyclic)amino-pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-15 US disclosed
US-20090227586-A1 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-10 US disclosed
US-20070293494-A1 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines DJUNG JANE F 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293494-A1 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines PRKCA, PRKCG, PRKCH ACP1 831/4885IRAK4 1916/4885KDM4E 981/4885
US-20090227586-A1 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES PRKCA, PRKCG, PRKCH ACP1 831/4885IRAK4 1916/4885KDM4E 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.